血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)
Multiplex Assay Kit for Angiotensin I Converting Enzyme 2 (ACE2) ,etc. by CBA (Cytometric Bead Array)
ACEH; ACEII; ACE-II; Peptidyl-Dipeptidase A; ACE-related carboxypeptidase; Angiotensin-converting enzyme homolog; Metalloprotease MPROT15
- 編號CMB886Ra
- 物種Rattus norvegicus (Rat，大鼠)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長4h
- 檢測范圍0.0488-50ng/mL
- 靈敏度最小可檢測劑量小于等于0.0163ng/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T
- 價(jià)格¥ 3637¥ 5196
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 80-98 | 88 |
| EDTA plasma(n=5) | 79-92 | 89 |
| heparin plasma(n=5) | 96-103 | 101 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-97% | 84-95% | 94-101% | 86-93% |
| EDTA plasma(n=5) | 85-99% | 93-102% | 93-105% | 82-104% |
| heparin plasma(n=5) | 91-99% | 95-104% | 80-92% | 84-98% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1、向?qū)嶒?yàn)板每孔內(nèi)加入200μL分析緩沖液以預(yù)濕；
2、實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
3、加樣（標(biāo)準(zhǔn)品、樣本、磁珠），標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，25°C酶標(biāo)板振蕩器孵育2小時(shí)；
4、磁吸甩干，加檢測溶液A 100μL，25°C酶標(biāo)板振蕩器孵育1小時(shí)；
5、磁吸甩干，加檢測溶液B 100μL，25°C振動(dòng)孵育30分鐘；
6、磁吸洗板1次；
7、加鞘液100μL，旋渦震蕩10分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)抗體包被于磁性微球表面，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)抗體，加入PE標(biāo)記的親和素，用流式細(xì)胞儀讀數(shù)。MFI值和樣品中的血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法)濃度呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| EPB886Ra61 | 血管緊張素轉(zhuǎn)化酶2(ACE2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB886Ra61 | 血管緊張素轉(zhuǎn)化酶2(ACE2)活性蛋白 | Cell?culture;?Activity?Assays. |
| APB886Ra01 | 血管緊張素轉(zhuǎn)化酶2(ACE2)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPB886Ra01 | 血管緊張素轉(zhuǎn)化酶2(ACE2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB886Ra02 | 血管緊張素轉(zhuǎn)化酶2(ACE2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB886Ra01 | 血管緊張素轉(zhuǎn)化酶2(ACE2)多克隆抗體 | WB; IHC |
| MAB886Ra23 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB |
| MAB886Ra22 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB |
| MAB886Ra24 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB |
| MAB886Ra25 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | ICC/IF |
| MAB886Ra21 | 血管緊張素轉(zhuǎn)化酶2(ACE2)單克隆抗體 | WB |
| SEB886Ra | 血管緊張素轉(zhuǎn)化酶2(ACE2)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB886Ra | 血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| CMB886Ra | 血管緊張素轉(zhuǎn)化酶2(ACE2)等多因子檢測試劑盒(流式熒光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Nature Medicine | Angiotensin-Converting Enzyme 2 Overexpression Remarkably Ameliorated Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE Inhibition[MolMed: 10_11_liu] |
| Journal of Cancer Therapy | Plasma Levels of Angiotensin-Converting Enzymes 1 and 2 and AGTR2 (T1247G and A5235G) Gene Polymorphisms Are Associated to Breast Cancer Progression.[Scirp: Source] |
| Reprod Toxicol.? | ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats[Pubmed:25205467] |
| Intensive Care Medicine Experimental | Angiotensin converting enzymes in patients with acute respiratory distress syndrome[Content: 3] |
| Journal of Chromatography A | Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis[S0021967317311858] |
| Journal of Clinical Pharmacy and Therapeutics | Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites.[pubmed:28895159] |
| Innate?Immunity? | Lipoxin A attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis[Pubmed:29969931] |
| Journal of?Surgical?Research | Impact of angiotensin-converting enzyme 2 levels on postoperative pneumonia after esophagectomy[Pubmed:29506841] |
| canadian journal of physiology and pharmacology | Could cardioprotective effect of ACE2 activator “diminazene aceturate” is more potent than ACE inhibitor “Enalapril” on acute myocardial infarction in rats?[Pubmed: 30840489] |
| Intensive Care Medicine | Angiotensin-converting enzymes in acute respiratory distress syndrome[] |
| BioMed Research International | AVE 0991 Attenuates Pyroptosis and Liver Damage after Heatstroke by Inhibiting the ROS-NLRP3 Inflammatory Signalling Pathway[] |
| Heart?and?vessels | Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS axis and coronary heart disease[Pubmed: 31359146] |
| Medicine | Alteration and association between serum ACE2/angiotensin (1-7)/Mas axis and oxidative stress in chronic kidney disease: A pilot study[Pubmed: 32756181] |
| American Journal of Respiratory and Critical Care Medicine | Equilibrium Angiotensin Metabolite Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin Converting Enzyme Inhibition[Pubmed: 32628511] |
| Clinical Research in Cardiology | Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease[33280062] |
| Clinical & Translational Immunology | Pattern of circulating SARS?\CoV?\2?\specific antibody?\secreting and memory B?\cell generation in patients with acute COVID?\19[33552508] |
| researchsquare | Novel transgenic mice with Cre-dependent co-expression of GFP and human ACE2: a safe tool for study of COVID-19 pathogenesis[33855640] |
| Viruses | Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera[] |
| Sci Rep | Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury[34907257] |
| European Journal of Clinical Investigation | Angiotensin‐converting enzyme 2 and Transmembrane protease serine 2 in female and male patients with end‐stage kidney disease[Pubmed:35366343] |
| Metabolites | Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats[Pubmed:35448480] |